

Reimbursement of this drug cannot be authorized as its prior authorization criteria cannot be determined at this time.

We evaluate each drug to determine the list of indications and criteria that could lead to a reimbursement under the prior authorization program.

To conclude the evaluation of this drug, we need data about the drug sanctioned by the scientific community and government agencies. At the moment, some of this data is still not available.

Sources of this data may include: product monograph of a drug approved by Health Canada, clinical practice guidelines, peer-reviewed medical journals and recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS).

This evaluation is not intended to question the opinion of your attending physician or any other professional opinion.